Real-World study tracks safety of ulcerative colitis drug in over 1,100 patients
NCT ID NCT03824561
Summary
This study monitored the long-term safety and effectiveness of the drug Entyvio (vedolizumab) in people with moderate to severe ulcerative colitis. It observed over 1,100 patients in Japan who were already receiving the drug as part of their regular care. The goal was to collect real-world information on side effects and how well the treatment worked over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.